1. European Centre for Disease Prevention and Control. Variants of interest and concern in the EU/EEA. Available at https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba5 2022.
2. Cross-neutralization of SARS-CoV-2 B1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected;Anna;J Infect,2021
3. The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS-CoV-2 replication in vitro;Anna;Microorganisms,2022
4. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS “Fondazione Pascale” cancer center (Naples, Italy);Antonietta;Infect Agent Cancer,2022
5. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study);Takeshi;Clin Infect Dis,2022